Table 2.
Fourteen studies which reported patients with CAPA in whom isavuconazole treatment was used.
| References | Country | Total No of Patients with CAPA | No of the Patients Who Received Antifungal Treatment | Treated with ISA Monotherapy (Usually as 1st Line) |
Treated with VORI Monotherapy (Usually as 1st Line) |
Treated with L-AmB Monotherapy (Usually as 1st Line) |
Other Antifungals in Monotherapy | Combined or Sequential Treatment | Outcome in ISA-Treated Patients |
|---|---|---|---|---|---|---|---|---|---|
| Falces et al., 2020 [46] | Spain | 10 | 8 | None | 2/8 (25%) | None | 2/8 (25%) AmB | VORI + CASP in 1 AmB followed by ISA in 1 Sequential combination treatment: MICA + VORI > AmB + ISA in 1 ANID followed by AmB in 1 |
No data |
| Gangneux et al., 2020 [47] | France | 9 | 7 | All treated with VORI or ISA, no further details | None | None | None | No data | |
| Rutsaert et al., 2020 [3] | Belgium | 7 | 6 | 2/6 (33%) | 4/6 (67%) | None | None | None | 2/6 patients died; no data on which treatment they received |
| Koehler et al., 2020 [8] | Germany | 5 | 5 | 1/5 (20%) | 2/5 (40%) | None | 2/5 CASP followed by VORI | None | The only patient treated with ISA died, no cause of death provided |
| Antinori et al., 2020 [45] | Italy | 1 | 1 | 1/1 (100%) | None | None | None | - | Died soon after starting treatment |
| Prattes et al., 2021 [48] | Europe, USA, Pakistan | 109 | 99 | 36/99 (36%) * | 52/99 (53%) | 17/99 (17%) | POSA 4/99 (4%), Echinocandins 13/99 (13%), Deoxycholate AmB 3/99 (3%) | 18/99 (18%) VORI or ISA combined with echinocandin or L-AmB | No data |
| Lahmer et al., 2021 [53] | Germany | 11 | 11 | 1/11 (9%) | 5/11 (45%) | 5/11 (45%) | None | None | No data for ISA treated patient |
| Hatzl et al., 2021 [57] | Austria | 9 | 9 | 3/9 (33%) | None | None | 6/9 (67%) POSA | None | No data for 3 ISA treated patients |
| Fekkar et al., 2021 [52] | France | 7 | 6 | None | None | None | CASP | VORI + CASP in 3 L-AmB + CASP in 1 VORI/L-AmB/CASP/ISA in 1 VORI/CASP/L-AmB in 1 |
Success in the single patient who received combination treatment including ISA |
| Paramythiotou et al., 2021 [50] | Greece | 6 | 6 | 5/6 (83%) | None | None | CASP | Sequential treatment CASP > L-AmB in 1 | Two patients alive at the last follow up and still on ISA treatment, 3 patients died, mainly due to MDR A. baumanni infection |
| Machado et al., 2021 [51] | Spain | 8 | 5 | 4/5 (80%) | None | 1/5 (20%) | None | None | All 5 died due to CAPA |
| Wasylyshyn et al., 2021 [54] | UK | 3 | 2 | None | None | None | None | Sequential treatment VORI > ISA in both | Both ISA treated patients alive at 12 weeks. |
| Gangneux et al., 2022 [49] | France | 76 | 58 (76%) | 11/58 (19%) *° | 44/58 (76%) | 20/58 (28%) | CASP 16 (28%), unspecified 5 (9%) | 29/58 more than one type | No data |
| de Almeida et al., 2022 [55] | Brazil | 14 | 12 | None | 8/12 (%) | 1/12 (%) | - | 2 days of L-AmB + ISA, followed by ISA in 1 Sequential monotherapy VORI > L-AmB and L-AmB > VORI in 2 |
The only patient treated with a combination containing ISA: died on day 19 after diagnosis of CAPA; no direct cause of death provided |
* changes or sequential therapy details not available; ° not specified if all given in monotherapy. Abbreviations: ANID, anidulafungin; AmB, amphotericin B; CASP, caspofungin; ISA, isavuconazole; L-AmB, liposomal amphotericin B; MICA, micafungin; POSA, posaconazole; UK, United Kingdom; USA, United States of America; VORI, voriconazole.